Our study provides valuable insight into the potential of MAOB as a novel predictor of clinical outcomes and suggests that enhancing MAOB expression or enzyme activity could be a promising therapeutic strategy for ccRCC. The gene discussed is MAOB; the disease is nonpapillary renal cell carcinoma.